{
    "info": {
        "nct_id": "NCT05665738",
        "official_title": "Two-fraction High Dose Rate Brachytherapy as Monotherapy Delivered Three Hours Apart in Localized Prostate Cancer: A Pilot Study",
        "inclusion_criteria": "1. Participants must have histologically or cytologically confirmed diagnosis of prostate adenocarcinoma.\n2. National Comprehensive Cancer Network low to intermediate risk stratification.\n3. No prior treatment for prostate cancer and no prior androgen deprivation therapy.\n4. Age >=18 years.\n5. Eastern Cooperative Oncology Group (ECOG) performance status <2 (Karnofsky >60%.\n6. Eligible to undergo High dose rate (HDR) brachytherapy as monotherapy as determined by the treating radiation oncologist.\n7. Ability to understand and the willingness to sign a written informed consent document.\n8. Human immunodeficiency virus (HIV)-infected individuals on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.\n9. For participants with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.\n10. Individuals with a history of hepatitis C virus (HCV) infection must have been treated and cured. For individuals with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.\n11. Individuals with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
        "exclusion_criteria": "1. Any prior treatment for prostate cancer.\n2. Any prior androgen deprivation therapy.\n3. Is currently receiving any other investigational agents.\n4. Abnormal pre-brachytherapy assessment raising concern for undergoing HDR brachytherapy procedure.\n5. Contraindications to general anesthesia.\n6. Contraindications to radiotherapy.\n7. Prior cryosurgery or cryotherapy to the prostate.\n8. Prior transurethral resection of the prostate within the previous 6 months.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Human immunodeficiency virus (HIV)-infected individuals on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.",
            "criterions": [
                {
                    "exact_snippets": "Human immunodeficiency virus (HIV)-infected individuals",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "on effective anti-retroviral therapy",
                    "criterion": "anti-retroviral therapy",
                    "requirements": [
                        {
                            "requirement_type": "effectiveness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "undetectable viral load within 6 months",
                    "criterion": "HIV viral load",
                    "requirements": [
                        {
                            "requirement_type": "detectability",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "timeframe",
                            "expected_value": "within 6 months"
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. National Comprehensive Cancer Network low to intermediate risk stratification.",
            "criterions": [
                {
                    "exact_snippets": "National Comprehensive Cancer Network low to intermediate risk stratification",
                    "criterion": "NCCN risk stratification",
                    "requirements": [
                        {
                            "requirement_type": "risk category",
                            "expected_value": [
                                "low",
                                "intermediate"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Individuals with a history of hepatitis C virus (HCV) infection must have been treated and cured. For individuals with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.",
            "criterions": [
                {
                    "exact_snippets": "history of hepatitis C virus (HCV) infection ... must have been treated and cured",
                    "criterion": "history of hepatitis C virus (HCV) infection",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "treated and cured"
                        }
                    ]
                },
                {
                    "exact_snippets": "HCV infection who are currently on treatment ... eligible if they have an undetectable HCV viral load",
                    "criterion": "HCV infection (currently on treatment)",
                    "requirements": [
                        {
                            "requirement_type": "HCV viral load",
                            "expected_value": "undetectable"
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. For participants with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.",
            "criterions": [
                {
                    "exact_snippets": "evidence of chronic hepatitis B virus (HBV) infection",
                    "criterion": "chronic hepatitis B virus (HBV) infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "the HBV viral load must be undetectable on suppressive therapy, if indicated",
                    "criterion": "HBV viral load",
                    "requirements": [
                        {
                            "requirement_type": "detectability",
                            "expected_value": "undetectable"
                        },
                        {
                            "requirement_type": "suppressive therapy",
                            "expected_value": "if indicated"
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Age >=18 years.",
            "criterions": [
                {
                    "exact_snippets": "Age >=18 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. No prior treatment for prostate cancer and no prior androgen deprivation therapy.",
            "criterions": [
                {
                    "exact_snippets": "No prior treatment for prostate cancer",
                    "criterion": "prior treatment for prostate cancer",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "no prior androgen deprivation therapy",
                    "criterion": "prior androgen deprivation therapy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Ability to understand and the willingness to sign a written informed consent document.",
            "criterions": [
                {
                    "exact_snippets": "Ability to understand",
                    "criterion": "cognitive ability to understand informed consent",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "willingness to sign a written informed consent document",
                    "criterion": "willingness to sign informed consent",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Eligible to undergo High dose rate (HDR) brachytherapy as monotherapy as determined by the treating radiation oncologist.",
            "criterions": [
                {
                    "exact_snippets": "Eligible to undergo High dose rate (HDR) brachytherapy as monotherapy as determined by the treating radiation oncologist.",
                    "criterion": "eligibility for HDR brachytherapy as monotherapy",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "determined by",
                            "expected_value": "treating radiation oncologist"
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Participants must have histologically or cytologically confirmed diagnosis of prostate adenocarcinoma.",
            "criterions": [
                {
                    "exact_snippets": "histologically or cytologically confirmed diagnosis of prostate adenocarcinoma",
                    "criterion": "prostate adenocarcinoma diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histological",
                                "cytological"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must be MALE",
            "criterions": [
                {
                    "exact_snippets": "Must be MALE",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "male"
                        }
                    ]
                }
            ]
        },
        {
            "line": "11. Individuals with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.",
            "criterions": [
                {
                    "exact_snippets": "prior or concurrent malignancy",
                    "criterion": "malignancy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": [
                                "prior",
                                "concurrent"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen",
                    "criterion": "malignancy natural history or treatment",
                    "requirements": [
                        {
                            "requirement_type": "potential to interfere with safety or efficacy assessment of investigational regimen",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Eastern Cooperative Oncology Group (ECOG) performance status <2 (Karnofsky >60%.",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status <2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Karnofsky >60%",
                    "criterion": "Karnofsky performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": ">",
                                "value": 60,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "6. Contraindications to radiotherapy.",
            "criterions": [
                {
                    "exact_snippets": "Contraindications to radiotherapy",
                    "criterion": "contraindications to radiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Prior transurethral resection of the prostate within the previous 6 months.",
            "criterions": [
                {
                    "exact_snippets": "Prior transurethral resection of the prostate within the previous 6 months.",
                    "criterion": "transurethral resection of the prostate",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Any prior androgen deprivation therapy.",
            "criterions": [
                {
                    "exact_snippets": "Any prior androgen deprivation therapy",
                    "criterion": "androgen deprivation therapy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Contraindications to general anesthesia.",
            "criterions": [
                {
                    "exact_snippets": "Contraindications to general anesthesia",
                    "criterion": "contraindications to general anesthesia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Is currently receiving any other investigational agents.",
            "criterions": [
                {
                    "exact_snippets": "currently receiving any other investigational agents",
                    "criterion": "receipt of investigational agents",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Any prior treatment for prostate cancer.",
            "criterions": [
                {
                    "exact_snippets": "Any prior treatment for prostate cancer.",
                    "criterion": "prior treatment for prostate cancer",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Prior cryosurgery or cryotherapy to the prostate.",
            "criterions": [
                {
                    "exact_snippets": "Prior cryosurgery or cryotherapy to the prostate.",
                    "criterion": "cryosurgery to the prostate",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior cryosurgery or cryotherapy to the prostate.",
                    "criterion": "cryotherapy to the prostate",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Abnormal pre-brachytherapy assessment raising concern for undergoing HDR brachytherapy procedure.",
            "criterions": [
                {
                    "exact_snippets": "Abnormal pre-brachytherapy assessment raising concern for undergoing HDR brachytherapy procedure",
                    "criterion": "pre-brachytherapy assessment",
                    "requirements": [
                        {
                            "requirement_type": "abnormality",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "clinical concern for HDR brachytherapy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}